UAB 1356: A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

Grant

Date/time Interval

  • April 16, 2015 - April 15, 2018
  • Total Award Amount

  • 82005.00
  • Direct Costs

  • 65085.00
  • Sponsor Award Id

  • Contributor

  • Eckhoff, Devin   Investigator  
  • Gray, Stephen   Investigator  
  • White, Jared   Investigator